GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (FRA:5GV) » Definitions » Ending Cash Position

Genovis AB (FRA:5GV) Ending Cash Position : €13.70 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genovis AB Ending Cash Position?

Genovis AB's Ending Cash Position for the quarter that ended in Sep. 2024 was €13.70 Mil.

Genovis AB's quarterly Ending Cash Position declined from Mar. 2024 (€12.09 Mil) to Jun. 2024 (€12.03 Mil) but then increased from Jun. 2024 (€12.03 Mil) to Sep. 2024 (€13.70 Mil).

Genovis AB's annual Ending Cash Position declined from Dec. 2021 (€7.92 Mil) to Dec. 2022 (€6.63 Mil) but then increased from Dec. 2022 (€6.63 Mil) to Dec. 2023 (€11.02 Mil).

Genovis AB Ending Cash Position Historical Data

The historical data trend for Genovis AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB Ending Cash Position Chart

Genovis AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 4.34 7.92 6.63 11.02

Genovis AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.07 11.02 12.09 12.03 13.70

Genovis AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Genovis AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6.51+4.509
=11.02

Genovis AB's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=11.962+1.738
=13.70

Genovis AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Genovis AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Genovis AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (FRA:5GV) » Definitions » Ending Cash Position
Comparable Companies
OSTO:VICO OSTO:EGTX OSTO:HNSA OSTO:IBT B OSTO:FLUO OSTO:XSPRAY OSTO:BINV OSTO:CALTX OSTO:ONCO OSTO:CANTA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
GENO:Sweden
Address
Scheelevagen 2, Box 790, Lund, SWE, SE-220 07
Website
https://www.genovis.com
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.

Genovis AB Headlines

No Headlines